Featured Research

from universities, journals, and other organizations

Immune system-based therapy produces lasting remissions in melanoma patients, study reports

Date:
March 3, 2014
Source:
Dana-Farber Cancer Institute
Summary:
Nivolumab, a drug that unleashes the immune system to attack cancer, has shown to produce lasting remissions and hold the disease in check – for more than two years, in some cases – in many patients with advanced melanoma, according to a new study. The clinical trial involved 107 patients with advanced melanoma that no longer responded to other treatments. They received nivolumab intravenously every other week for up to 96 weeks. After one year, 62 percent of the patients were alive. After two years, 43 percent were alive. "These are striking results for patients with metastatic melanoma," said the study's senior author.

A drug that unleashes the immune system to attack cancer can produce lasting remissions and hold the disease in check -- for more than two years, in some cases -- in many patients with advanced melanoma, according to a new study by researchers at Dana-Farber Cancer Institute, Johns Hopkins University, Yale University, and allied institutions.

The study, published online today, March 3, by the Journal of Clinical Oncology, provides the longest-term look so far at how melanoma patients have fared since receiving the drug, nivolumab, in a phase I clinical trial. The results indicate that the benefits of nivolumab not only occur quickly but can persist, even in some cases where use of the drug is discontinued.

The clinical trial involved 107 patients with advanced melanoma that no longer responded to other treatments. They received nivolumab intravenously every other week for up to 96 weeks. After one year, 62 percent of the patients were alive. After two years, 43 percent were alive.

"These are striking results for patients with metastatic melanoma," said the study's senior author F. Stephen Hodi, MD, director of the Melanoma Treatment Center at Dana-Farber. "This study provides the first demonstration of the long-term benefits this treatment approach can produce."

Nivolumab is one of a new generation of drugs that essentially releases the brakes on an immune system attack on cancer. The drug blocks PD-1, a protein on immune system T cells that restrains them from leading a charge on tumor cells. By interfering with PD-1, nivolumab allows the attack to proceed.

The side effects of the treatment were consistent with those observed in previous studies of the drug. The most common adverse experiences were fatigue, rash, and diarrhea, most of which occurred in the first six months of therapy. Prolonged exposure to the drug didn't produce cumulative negative effects, the investigators report.

One of the most noteworthy findings of the study is that, in many patients, tumors either remained the same size or continued to recede even after the treatment period was over. "This suggests that blockade PD-1 may reset the equilibrium between the immune system and the tumor, keeping tumor growth in check," remarked Hodi, who is also the director of the Center for Immuno-Oncology at Dana-Farber.

Another intriguing discovery is that overall survival times for patients in the trial were considerably longer than the periods in which the disease did not worsen. In other words, even in patients who developed small new melanoma growths after treatment, the disease often remained under control. That is far different from the usual sequence of events, in which the appearance of new growths often heralds a full-scale return of the disease, Hodi said.

The effectiveness of nivolumab in these patients suggests that combining the drug with other immune system-based therapies may prove even more potent, the authors indicate. Clinical trials are already under way to assess such a combined approach.


Story Source:

The above story is based on materials provided by Dana-Farber Cancer Institute. Note: Materials may be edited for content and length.


Journal Reference:

  1. S. L. Topalian, M. Sznol, D. F. McDermott, H. M. Kluger, R. D. Carvajal, W. H. Sharfman, J. R. Brahmer, D. P. Lawrence, M. B. Atkins, J. D. Powderly, P. D. Leming, E. J. Lipson, I. Puzanov, D. C. Smith, J. M. Taube, J. M. Wigginton, G. D. Kollia, A. Gupta, D. M. Pardoll, J. A. Sosman, F. S. Hodi. Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab. Journal of Clinical Oncology, 2014; DOI: 10.1200/JCO.2013.53.0105

Cite This Page:

Dana-Farber Cancer Institute. "Immune system-based therapy produces lasting remissions in melanoma patients, study reports." ScienceDaily. ScienceDaily, 3 March 2014. <www.sciencedaily.com/releases/2014/03/140303163143.htm>.
Dana-Farber Cancer Institute. (2014, March 3). Immune system-based therapy produces lasting remissions in melanoma patients, study reports. ScienceDaily. Retrieved September 20, 2014 from www.sciencedaily.com/releases/2014/03/140303163143.htm
Dana-Farber Cancer Institute. "Immune system-based therapy produces lasting remissions in melanoma patients, study reports." ScienceDaily. www.sciencedaily.com/releases/2014/03/140303163143.htm (accessed September 20, 2014).

Share This



More Health & Medicine News

Saturday, September 20, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Could Grief Affect The Immune Systems Of Senior Citizens?

Could Grief Affect The Immune Systems Of Senior Citizens?

Newsy (Sep. 19, 2014) The study found elderly people are much more likely to become susceptible to infection than younger adults going though a similar situation. Video provided by Newsy
Powered by NewsLook.com
Jury Delivers Verdict in Salmonella Trial

Jury Delivers Verdict in Salmonella Trial

AP (Sep. 19, 2014) A federal jury has convicted three people in connection with an outbreak of salmonella poisoning five years ago that sickened hundreds of people and was linked to a number of deaths. (Sept. 19) Video provided by AP
Powered by NewsLook.com
How The 'Angelina Jolie Effect' Increased Cancer Screenings

How The 'Angelina Jolie Effect' Increased Cancer Screenings

Newsy (Sep. 19, 2014) Angelina's Jolie's decision to undergo a preventative mastectomy in 2013 inspired many women to seek early screenings for the disease. Video provided by Newsy
Powered by NewsLook.com
The Cost of Ebola

The Cost of Ebola

Reuters - Business Video Online (Sep. 18, 2014) As Sierra Leone prepares for a three-day "lockdown" in its latest bid to stem the spread of Ebola, Ciara Lee looks at the financial implications of fighting the largest ever outbreak of the disease. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins